Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis

Next Previous
Trial Profile

Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rilonacept (Primary)
  • Indications Pericarditis
  • Focus Registrational; Therapeutic Use
  • Acronyms RHAPSODY
  • Sponsors Kiniksa Pharmaceuticals

Most Recent Events

  • 02 Sep 2024 Results (n=17) assessing multicentric analysis of RP event rates in Italian pts after stopping long-term rilonacept, presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology.
  • 13 Nov 2023 Results of sub-group analysis presented at the American Heart Association Scientific Sessions 2023.
  • 07 Nov 2022 Results assessing efficacy, safety, and clinical decision making presented at the American Heart Association Scientific Sessions 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top